A new trading day began on Monday, with Acurx Pharmaceuticals Inc (NASDAQ: ACXP) stock price down -3.59% from the previous day of trading, before settling in for the closing price of $0.47. ACXP’s price has ranged from $0.30 to $3.33 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -7.84%. Meanwhile, its annual earnings per share averaged 42.53%. With a float of $25.53 million, this company’s outstanding shares have now reached $29.41 million.
Considering the fact that the conglomerate employs 4 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Acurx Pharmaceuticals Inc (ACXP) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Acurx Pharmaceuticals Inc is 13.17%, while institutional ownership is 11.88%. The most recent insider transaction that took place on Jan 06 ’25, was worth 25,000. In this transaction Director of this company bought 24,631 shares at a rate of $1.01, taking the stock ownership to the 27,708 shares. Before that another transaction happened on Jan 06 ’25, when Company’s Director bought 24,631 for $1.01, making the entire transaction worth $25,000. This insider now owns 137,183 shares in total.
Acurx Pharmaceuticals Inc (ACXP) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 42.53% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 15.59% during the next five years compared to -7.84% drop over the previous five years of trading.
Acurx Pharmaceuticals Inc (NASDAQ: ACXP) Trading Performance Indicators
Here are Acurx Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.93.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.70, a number that is poised to hit -0.12 in the next quarter and is forecasted to reach -0.51 in one year’s time.
Technical Analysis of Acurx Pharmaceuticals Inc (ACXP)
Compared to the last year’s volume of 3.12 million, its volume of 0.86 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 24.43%.
During the past 100 days, Acurx Pharmaceuticals Inc’s (ACXP) raw stochastic average was set at 20.80%, which indicates a significant increase from 13.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0689 in the past 14 days, which was higher than the 0.0436 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.4310, while its 200-day Moving Average is $0.8779. Nevertheless, the first resistance level for the watch stands at $0.4829 in the near term. At $0.5098, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.5296. If the price goes on to break the first support level at $0.4362, it is likely to go to the next support level at $0.4164. Now, if the price goes above the second support level, the third support stands at $0.3895.
Acurx Pharmaceuticals Inc (NASDAQ: ACXP) Key Stats
With a market capitalization of 13.41 million, the company has a total of 29,407K Shares Outstanding. Currently, annual sales are 0 K while annual income is -14,100 K. The company’s previous quarter sales were 0 K while its latest quarter income was -2,150 K.
